193 related articles for article (PubMed ID: 2943136)
1. Comparisons between the in vitro binding of two substituted benzamides and two butyrophenones to dopamine-D2 receptors in the rat striatum.
Hall H; Wedel I
Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):368-73. PubMed ID: 2943136
[TBL] [Abstract][Full Text] [Related]
2. Selective labelling of dopamine (D2) receptors in rat striatum by [3H]domperidone but not by [3H]spiperone.
Lazareno S; Nahorski SR
Eur J Pharmacol; 1982 Jul; 81(2):273-85. PubMed ID: 7117377
[TBL] [Abstract][Full Text] [Related]
3. Comparison of [3H]YM-09151-2 with [3H]spiperone and [3H]raclopride for dopamine d-2 receptor binding to rat striatum.
Terai M; Hidaka K; Nakamura Y
Eur J Pharmacol; 1989 Dec; 173(2-3):177-82. PubMed ID: 2576228
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand.
Hall H; Högberg T; Halldin C; Bengtsson S; Wedel I
Eur J Pharmacol; 1991 Aug; 201(1):1-10. PubMed ID: 1686586
[TBL] [Abstract][Full Text] [Related]
5. Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes.
Hamblin MW; Leff SE; Creese I
Biochem Pharmacol; 1984 Mar; 33(6):877-87. PubMed ID: 6712712
[TBL] [Abstract][Full Text] [Related]
6. Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites.
Malmberg A; Jerning E; Mohell N
Eur J Pharmacol; 1996 May; 303(1-2):123-8. PubMed ID: 8804920
[TBL] [Abstract][Full Text] [Related]
7. [3H]-domperidone labels only a single population of receptors which convert from high to low affinity for dopamine in rat brain.
Grigoriadis D; Seeman P
Naunyn Schmiedebergs Arch Pharmacol; 1986 Jan; 332(1):21-5. PubMed ID: 2869417
[TBL] [Abstract][Full Text] [Related]
8. Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum.
Zahniser NR; Dubocovich ML
J Pharmacol Exp Ther; 1983 Dec; 227(3):592-9. PubMed ID: 6655559
[TBL] [Abstract][Full Text] [Related]
9. Resolution of dopamine and serotonin receptor components of [3H]spiperone binding to rat brain regions.
List SJ; Seeman P
Proc Natl Acad Sci U S A; 1981 Apr; 78(4):2620-4. PubMed ID: 6941314
[TBL] [Abstract][Full Text] [Related]
10. Analysis of [3H]spiperone binding sites in the rat striatum and frontoparietal cortex by means of quantitative receptor autoradiography after inactivation of dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by sulpiride in the striatum.
Fuxe K; Meller E; Goldstein M; Benfenati F; Agnati LF
Neurosci Lett; 1986 Feb; 64(2):163-8. PubMed ID: 3960398
[TBL] [Abstract][Full Text] [Related]
11. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs.
Florijn WJ; Tarazi FI; Creese I
J Pharmacol Exp Ther; 1997 Feb; 280(2):561-9. PubMed ID: 9023264
[TBL] [Abstract][Full Text] [Related]
12. Binding of 3H-spiperone and 3H-(-)-sulpiride to dopamine D2 receptors in rat striatal membranes: methodological considerations and demonstration of the identical nature of the binding sites for the two ligands.
Urwyler S; Coward D
Naunyn Schmiedebergs Arch Pharmacol; 1987 Feb; 335(2):115-22. PubMed ID: 2951601
[TBL] [Abstract][Full Text] [Related]
13. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
Hancock AA; Marsh CL
Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
[TBL] [Abstract][Full Text] [Related]
14. Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2.
Niznik HB; Grigoriadis DE; Pri-Bar I; Buchman O; Seeman P
Naunyn Schmiedebergs Arch Pharmacol; 1985 Jun; 329(4):333-43. PubMed ID: 2863760
[TBL] [Abstract][Full Text] [Related]
15. Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography.
Seeman P; Tallerico T; Ko F
Synapse; 2003 Sep; 49(4):209-15. PubMed ID: 12827639
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the binding of [3H]spiperone and [3H]domperidone in homogenates of mammalian retina and caudate nucleus.
Watling KJ; Iversen LL
J Neurochem; 1981 Nov; 37(5):1130-43. PubMed ID: 7299392
[TBL] [Abstract][Full Text] [Related]
17. Chronic domperidone fails to increase striatal spiperone binding sites despite hyperprolactinemia: comparison with chronic haloperidol.
Morgan DG; Sinha YN; Finch CE
Neuroendocrinology; 1984 May; 38(5):407-10. PubMed ID: 6728123
[TBL] [Abstract][Full Text] [Related]
18. In vivo labelling of pituitary dopamine D-2 receptors in the male rat using [3H]-raclopride.
Köhler C; Karlsson-Boethius G
J Neural Transm; 1989; 76(1):13-28. PubMed ID: 2523467
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D2 receptor dissociation constant for spiperone: identical values using 3H-labeled agonist or 3H-labeled antagonist.
Seeman P; Grigoriadis D
Biochem Pharmacol; 1985 Nov; 34(22):4065-6. PubMed ID: 4062976
[No Abstract] [Full Text] [Related]
20. In vivo labelling of rat brain dopamine D-2 receptors. Stereoselective blockade by the D-2 antagonist raclopride and its enantiomer of 3H-spiperone, 3H-N,N-propylnorapomorphine and 3H-raclopride binding in the rat brain.
Köhler C; Karlsson-Boethius G
J Neural Transm; 1988; 73(2):87-100. PubMed ID: 2974879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
